Physician profile
Priscilla O Eich
NPI 1821308537
$1,586.86
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,073 · 2022: $514.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $608.45 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.51 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $193.86 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $140.42 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $117.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.04 | 2021 | |
| Merck Sharp & Dohme LLC | $43.87 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $43.64 | 2022 | |
| Mylan Specialty L.P. | $38.99 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $32.27 | 2021 | |
| Insmed, INC. | $30.91 | 2021 | |
| Advanced Respiratory, INC | $21.06 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.43 | 2021 | |
| Electromed, INC. | $14.69 | 2021 | |
| Novo Nordisk INC | $13.38 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $11.67 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priscilla Eich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.